tradingkey.logo

Daxor Corp

DXR
查看詳細走勢圖
12.895USD
+0.515+4.16%
收盤 12/19, 16:00美東報價延遲15分鐘
64.27M總市值
37.08本益比TTM

Daxor Corp

12.895
+0.515+4.16%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+4.16%

5天

+5.26%

1月

-2.26%

6月

+38.81%

今年開始到現在

+67.69%

1年

+54.43%

查看詳細走勢圖

TradingKey Daxor Corp股票評分

單位: USD 更新時間: 2025-10-27

操作建議

當前估值合理,機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價max_target_price。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Daxor Corp評分

相關信息

行業排名
28 / 30
全市場排名
544 / 4682
所屬行業
集合投資

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 1 分析師
買入
評級
23.500
目標均價
+82.88%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Daxor Corp亮點

亮點風險
Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.
業績增長期
公司處於發展階段,最新年度總收入2.22M美元
估值高估
公司最新PB估值1.60,處於3年歷史高位
機構減倉
最新機構持股100.09K股,環比減少11.19%
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉,最新持倉28.02K股

Daxor Corp新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Daxor Corp簡介

Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.
公司代碼DXR
公司Daxor Corp
CEOFeldschuh (Michael Richard)
網址https://www.daxor.com/

常見問題

Daxor Corp(DXR)的當前股價是多少?

Daxor Corp(DXR)的當前股價是 12.895。

Daxor Corp 的股票代碼是什麼?

Daxor Corp的股票代碼是DXR。

Daxor Corp股票的52週最高點是多少?

Daxor Corp股票的52週最高點是14.150。

Daxor Corp股票的52週最低點是多少?

Daxor Corp股票的52週最低點是6.550。

Daxor Corp的市值是多少?

Daxor Corp的市值是64.27M。

Daxor Corp的淨利潤是多少?

Daxor Corp的淨利潤為536.33K。

現在Daxor Corp(DXR)的股票是買入、持有還是賣出?

根據分析師評級,Daxor Corp(DXR)的總體評級為買入,目標價格為23.500。

Daxor Corp(DXR)股票的每股收益(EPS TTM)是多少

Daxor Corp(DXR)股票的每股收益(EPS TTM)是0.348。
KeyAI